TY - JOUR
T1 - Hiv treatment as prevention
T2 - Models, data, and questions-towards evidence-based decision-making
AU - The HIV Modelling Consortium Treatment as Prevention Editorial Writing Group
AU - Bärnighausen, Till
AU - Becker, Stephen
AU - Bendavid, Eran
AU - Bershteyn, Anna
AU - Blandford, John
AU - Boily, Marie Claude
AU - Burns, David
AU - Cambiano, Valentina
AU - Cohen, Myron S.
AU - Cremin, Íde
AU - Delva, Wim
AU - Dye, Christopher
AU - Eaton, Jeffrey W.
AU - Egger, Matthias
AU - Fraser, Christophe
AU - Galai, Noya
AU - Garnett, Geoff
AU - Ghys, Peter D.
AU - Hallett, Timothy B.
AU - Heaton, Laura
AU - Holmes, Charles B.
AU - Hontelez, Jan
AU - Jewell, Britta
AU - Keiser, Olivia
AU - Klein, Daniel
AU - Lima, Viviane
AU - Long, Elisa
AU - Lyerla, Rob
AU - Marais, Christiaan
AU - Meng, Fei
AU - Meyer-Rath, Gesine
AU - Miller, William C.
AU - Muraguri, Nicholas
AU - Nichols, Brooke E.
AU - Nigmatulina, Karima R.
AU - Over, Mead
AU - Padian, Nancy
AU - Phillips, Andrew
AU - Pretorius, Carel
AU - Rousseau, Christine
AU - Salomon, Joshua
AU - Sangrujee, Nalinee
AU - Serwadda, David
AU - Tanser, Frank
AU - Vesga, Juan F.
AU - Vickerman, Peter
AU - Walker, Damian
AU - Wang, Rui
AU - Welte, Alex
AU - White, Richard G.
PY - 2012/7/1
Y1 - 2012/7/1
N2 - Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.
AB - Antiretroviral therapy (ART) for those infected with HIV can prevent onward transmission of infection, but biological efficacy alone is not enough to guide policy decisions about the role of ART in reducing HIV incidence. Epidemiology, economics, demography, statistics, biology, and mathematical modelling will be central in framing key decisions in the optimal use of ART. PLoS Medicine, with the HIV Modelling Consortium, has commissioned a set of articles that examine different aspects of HIV treatment as prevention with a forward-looking research agenda. Interlocking themes across these articles are discussed in this introduction. We hope that this article, and others in the collection, will provide a foundation upon which greater collaborations between disciplines will be formed, and will afford deeper insights into the key factors involved, to help strengthen the support for evidence-based decision-making in HIV prevention.
UR - http://www.scopus.com/inward/record.url?scp=85032293737&partnerID=8YFLogxK
U2 - 10.1371/journal.pmed.1001259
DO - 10.1371/journal.pmed.1001259
M3 - Article
C2 - 22802739
AN - SCOPUS:85032293737
SN - 1549-1277
VL - 9
JO - PLoS Medicine
JF - PLoS Medicine
IS - 7
M1 - e1001259
ER -
